By Sahithya K · Reviewed by Divya Chandradhara · Published 12 November 2026

Every clinical trial in India needs freely given, informed, written consent from each trial subject before the subject takes part. Under the Third Schedule of the New Drugs and Clinical Trials Rules, 2019, the investigator explains the study verbally and through a patient information sheet in non-technical language, and the subject signs an Informed Consent Form approved by the Ethics Committee.

Informed consent rests on two documents: the patient information sheet, which explains the study, and the Informed Consent Form, which the trial subject signs. Under paragraph 2 of the Third Schedule of the NDCT Rules, both must be approved by the Ethics Committee and furnished to the Central Licencing Authority before use.

Any change to the consent documents must be approved by the Ethics Committee and submitted to the Central Licencing Authority before the change is implemented. A revised form used before both steps are complete is a deviation, and consent version history is a record reviewers and inspectors routinely check.

Table 3 of the Third Schedule lists sixteen essential elements the informed consent documents must cover, and six additional elements that may be required depending on the trial.

Table 1. Essential elements of informed consent (Third Schedule, Table 3)

#The documents must state
1That the study involves research, and the purpose of the research
2The expected duration of the subject’s participation
3The procedures to be followed, including all invasive procedures
4Any reasonably foreseeable risks or discomforts
5Any benefits reasonably expected, or that no benefit is expected
6Appropriate alternative procedures or therapies available
7How far confidentiality of records will be maintained, and who will have access to medical records
8The trial treatment schedule and, in randomised trials, the probability of assignment to each treatment
9Free medical management for injury, and financial compensation for trial-related injury or death
10Whom to contact for trial queries, subjects’ rights and in the event of injury
11Any anticipated prorated payment for participation
12The subject’s responsibilities in the trial
13That participation is voluntary, withdrawal is possible at any time and refusal carries no penalty or loss of benefits
14That the investigational product may fail to give the intended therapeutic effect
15In a placebo-controlled trial, that the placebo has no therapeutic effect
16Any other pertinent information

The additional elements cover the circumstances in which the investigator may end a subject’s participation without consent, additional costs to the subject, the consequences of withdrawal, notification of significant new findings, currently unforeseeable risks (including to an embryo or foetus) and the approximate number of subjects enrolled. Drafting consent documents that cover every element is usually part of medical writing for a trial.

The Third Schedule also prescribes a format for the Informed Consent Form. Alongside the study title, study number and the subject’s initials and name, it records the subject’s date of birth or age, address, qualification, occupation and annual income. It also records the name and address of a nominee and the nominee’s relationship to the subject.

The income and nominee fields exist for a reason specific to the Indian framework. Compensation for a non-permanent injury is commensurate with loss of wages under the Seventh Schedule, and the form records the nominee in its own words “for the purpose of compensation in case of trial related death”. Under the Third Schedule the investigator must also tell the subject, or the nominee, of the right to contact the sponsor to claim compensation. What happens after an injury is reported is set out in the SAE reporting guide.

Legally acceptable representatives and impartial witnesses

Where a trial subject is not able to give informed consent, for example an unconscious person, a minor or a person suffering from severe mental illness or disability, consent may be obtained from a legally acceptable representative. The Third Schedule describes a legally acceptable representative as a person able to give consent for, or authorise, an intervention in the patient as provided by the law of India.

Where the trial subject, or the legally acceptable representative, is unable to read or write, an impartial witness must be present during the entire informed consent process and must sign the consent form. Presence for part of the discussion does not meet the requirement.

In paediatric trials the subjects are legally unable to give written consent, so written informed consent is obtained from a parent or legal guardian. The Third Schedule adds three requirements:

  • Every paediatric participant should be informed about the study to the fullest extent possible, in language and terms the child can understand.

  • Where appropriate, the child should also assent to enrolment. Mature minors and adolescents should personally sign and date a separately designed written assent form.

  • A child’s wish to withdraw must be respected, although in therapeutic studies of serious or life-threatening diseases the investigator and parent or guardian may judge that withdrawal would endanger the child, in which case continued parental or guardian consent can be enough.

An audio-video recording of the informed consent process must be maintained by the investigator for vulnerable subjects in clinical trials of a New Chemical Entity or a New Molecular Entity, under paragraph 2(g) of the Third Schedule. The recording covers the procedure of giving information to the subject and the subject’s understanding of the consent.

For clinical trials of anti-HIV and anti-leprosy drugs, only an audio recording of each subject’s consent process is maintained.

The recording is a record the investigator keeps, which makes the site’s recording equipment, storage and confidentiality controls part of trial readiness. Clinical quality assurance reviews usually test this before the first subject is enrolled.

ICH E6(R3), the current ICH good clinical practice guideline, adopted on 6 January 2025, treats informed consent as an integral feature of ethical trial conduct. Its second principle says participation should be voluntary and based on a consent process that leaves participants, or their legally acceptable representatives, well informed, and it allows for technology to be used in informing participants and obtaining consent. In India the Third Schedule sets the binding requirements, and the investigator applies both.

Yes. The Third Schedule of the NDCT Rules requires freely given, informed, written consent from each trial subject in all trials. The investigator gives the information verbally and through a patient information sheet in non-technical language, and the subject signs an Informed Consent Form approved by the Ethics Committee.

A legally acceptable representative, meaning a person able to give consent for, or authorise, an intervention in the patient as provided by the law of India. This applies, for example, to an unconscious person, a minor or a person with severe mental illness or disability. For children, the parent or legal guardian consents.

When the trial subject or the legally acceptable representative is unable to read or write. The impartial witness must be present during the entire informed consent process and must sign the consent form. The requirement is set in paragraph 2 of the Third Schedule of the NDCT Rules, 2019.

For vulnerable subjects in clinical trials of a New Chemical Entity or New Molecular Entity, the investigator must keep an audio-video recording of the consent process. In trials of anti-HIV and anti-leprosy drugs, only an audio recording is kept. Both cover how information was given and the subject’s understanding.

Yes, but only after the Ethics Committee has approved the change and it has been submitted to the Central Licencing Authority. The revised documents cannot be used before both steps are complete. Subjects already enrolled are told of significant new findings that may affect their willingness to continue.

The Third Schedule format includes both because compensation is determined under the Seventh Schedule, where loss of wages is the basis for a non-permanent injury, and the nominee is recorded for the purpose of compensation in case of trial-related death. Recording both at enrolment keeps the information available if a claim later arises.

About this guide

This guide is based on paragraph 2 and Table 3 of the Third Schedule of the New Drugs and Clinical Trials Rules, 2019, in the gazette text published by the Central Drugs Standard Control Organisation, and on ICH E6(R3). It was written by Sahithya K, and reviewed by Divya Chandradhara It states the position as at 12 November 2026 and is reviewed every six months and after any amendment to the Rules.